PCR-based amplification of circulating RNAs as prognostic and predictive biomarkers - Focus on neuroblastoma - PubMed (original) (raw)
PCR-based amplification of circulating RNAs as prognostic and predictive biomarkers - Focus on neuroblastoma
Sam C Brownhill et al. Pract Lab Med. 2016.
Abstract
Metastatic disease is a major challenge for cancer cure, haematogenous spread and subsequent growth of tumour cells at distant sites being the cause of most cancer deaths. Molecular characterization and detection of the tumour cells responsible for haematogenous spread may increase understanding of the biology of metastasis, help improve patient management and allow evaluation of novel treatments to prevent and eradicate this disease. The bone marrow is a common site to which tumour cells metastasize, from which they may re-circulate to other organs with a favourable microenvironment for growth. The detection of tumour cells in blood suggests one route for metastasis, and provides an accessible, minimally invasive liquid sample through which it may be possible to monitor and detect minimal disease and early signs of metastasis. Significant improvements in the sensitivity and specificity of tumour cell detection have been made, such that it is now possible to unambiguously detect a single tumour cell in over 10 million normal cells. However, the clinical impact of such low level disease and how to interpret the natural variation that can arise from sequential sampling of bone marrow aspirates and blood is currently largely unknown. This commentary will focus on the technical advancements and application of reverse transcriptase polymerase chain reaction to detect cancer mRNAs in bone marrow and blood, and discuss the potential clinical impact of this test in neuroblastoma.
Keywords: Blood; Bone marrow; Circulating; Disseminating; Neuroblastoma; RTqPCR; Tumour cells.
Similar articles
- Detection, clinical relevance and specific biological properties of disseminating tumour cells.
Pantel K, Brakenhoff RH, Brandt B. Pantel K, et al. Nat Rev Cancer. 2008 May;8(5):329-40. doi: 10.1038/nrc2375. Nat Rev Cancer. 2008. PMID: 18404148 Review. - New technologies for the detection of circulating tumour cells.
Gerges N, Rak J, Jabado N. Gerges N, et al. Br Med Bull. 2010;94:49-64. doi: 10.1093/bmb/ldq011. Epub 2010 Apr 23. Br Med Bull. 2010. PMID: 20418405 Review. - Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group.
Burchill SA, Beiske K, Shimada H, Ambros PF, Seeger R, Tytgat GA, Brock PR, Haber M, Park JR, Berthold F. Burchill SA, et al. Cancer. 2017 Apr 1;123(7):1095-1105. doi: 10.1002/cncr.30380. Epub 2016 Dec 16. Cancer. 2017. PMID: 27984660 Review. - Early clinical evaluation of neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA.
Burchill SA, Bradbury FM, Selby P, Lewis IJ. Burchill SA, et al. Eur J Cancer. 1995;31A(4):553-6. doi: 10.1016/0959-8049(95)00053-l. Eur J Cancer. 1995. PMID: 7576966 Clinical Trial. - Detection of low numbers of neuroblastoma cells in vitro.
Lai PS, Chee S, Chiu LL, Sano K. Lai PS, et al. Ann Acad Med Singap. 1997 Jul;26(4):415-20. Ann Acad Med Singap. 1997. PMID: 9395801
Cited by
- Minimal Residual Disease Detected by the 7NB-mRNAs ddPCR Assay Is Associated with Disease Progression in High-Risk Neuroblastoma Patients: A Prospective Multicenter Observational Study in Japan.
Nishimura N, Ishida T, Yokota I, Matsumoto K, Shichino H, Fujisaki H, Sarashina T, Kamijo T, Takimoto T, Iehara T, Tajiri T, On Behalf Of The Jccg Neuroblastoma Committee. Nishimura N, et al. Biology (Basel). 2023 Oct 20;12(10):1350. doi: 10.3390/biology12101350. Biology (Basel). 2023. PMID: 37887060 Free PMC article. - Higher levels of minimal residual disease in peripheral blood than bone marrow before 1st and 2nd relapse/regrowth in a patient with high‑risk neuroblastoma: A case report.
Inoue S, Win KHN, Mon CY, Fujikawa T, Hyodo S, Uemura S, Ishida T, Mori T, Hasegawa D, Kosaka Y, Nishimura A, Nakatani N, Nino N, Tamura A, Yamamoto N, Nozu K, Nishimura N. Inoue S, et al. Oncol Lett. 2023 Jul 14;26(3):369. doi: 10.3892/ol.2023.13955. eCollection 2023 Sep. Oncol Lett. 2023. PMID: 37559575 Free PMC article. - BPTF in bone marrow provides a potential progression biomarker regulated by TFAP4 through the PI3K/AKT pathway in neuroblastoma.
Jiang C, Yang Y, He S, Yue Z, Xing T, Chu P, Yang W, Chen H, Zhao X, Yu Y, Zhang X, Su Y, Guo Y, Ma X. Jiang C, et al. Biol Proced Online. 2023 May 11;25(1):11. doi: 10.1186/s12575-023-00200-7. Biol Proced Online. 2023. PMID: 37170211 Free PMC article. - Minimal residual disease detected by droplet digital PCR in peripheral blood stem cell grafts has a prognostic impact on high-risk neuroblastoma patients.
Nino N, Ishida T, Nakatani N, Lin KS, Win KHN, Mon CY, Nishimura A, Inoue S, Tamura A, Yamamoto N, Uemura S, Saito A, Mori T, Hasegawa D, Kosaka Y, Nozu K, Nishimura N. Nino N, et al. Heliyon. 2022 Oct 8;8(10):e10978. doi: 10.1016/j.heliyon.2022.e10978. eCollection 2022 Oct. Heliyon. 2022. PMID: 36276741 Free PMC article. - Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy.
Asgharzadeh S, Marachelian A, Villablanca JG, Liu WY, Kennedy R, Sposto R, Naranjo A, Tenney S, Yu AL, Ozkaynak MF, Sondel PM, Park JR, Seeger RC. Asgharzadeh S, et al. Pediatr Blood Cancer. 2022 Sep;69(9):e29719. doi: 10.1002/pbc.29719. Epub 2022 Apr 20. Pediatr Blood Cancer. 2022. PMID: 35441784 Free PMC article.
References
- Roth M.S., Antin J.H., Ash R., Terry V.H., Gotlieb M., Silver S.M., Ginsburg D. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood. 1992;79(1):276–282. - PubMed
- West D.C., Grier H.E., Swallow M.M., Demetri G.D., Granowetter L., Sklar J. Detection of circulating tumor cells in patients with Ewing’s sarcoma and peripheral primitive neuroectodermal tumor. J. Clin. Oncol. 1997;15(2):583–588. - PubMed
- de Alava E., Lozano M.D., Patiño A., Sierrasesúmaga L., Pardo-Mindán F.J. Ewing family tumors: potential prognostic value of reverse-transcriptase polymerase chain reaction detection of minimal residual disease in peripheral blood samples. Diagn. Mol. Pathol. 1998;7(3):152–157. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources